APMD · Apnimed, Inc.
$18.51
+1.92 (+11.54%)
At close · Oct 20
Return incl. dividend (before tax)
Going-concern doubt
— cleared Sep 8, 2026
The latest filing states the doubt was alleviated.
“The Company has evaluated whether there are certain conditions and events, considered in the aggregate, that raise substantial doubt about the Company's ability to continue as a going concern within the twelve months after the date that these consolidated financial statements are issued. The Company believes that its existing cash and cash equivalents of $172.8 million as of June 30, 2026, together with the additional proceeds received from the IPO, will be sufficient to allow the Company to fund operations at least twelve months from the date that the financial statements are issued.”View the 10-Q filed Sep 8, 2026
Market Cap
$771.42M
Shares
41.63M
Volume · Oct 20
310.01K
Avg daily vol (57 sessions)
525.14K
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$18.51
Open$16.64
Day$16.43–18.80
Available close range$16.60–32.55
Avg vol 30d555K
Short int1.8M · 4.2% float · 2.1d
Short vol51%
DataJul 2026–Oct 2026
Filing10-Q · Sep 8
The closing range uses available history since Jul 31, 2026; less than a full year is stored.
Up next
filed Sep 8, 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
—
Trailing 12 months
Revenue growth YoY
-29.4%
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$132.54M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+580.5%
Year over year · more shares
Price change (1Y)
—
Trailing year
Short interest
4.2%
Latest settlement · 2.1 days to cover
Quarterly results
Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Sell
Momentum
Limited
Sentiment
Neutral
Fundamentals
Limited
Quant / Vol
Very High
Market backdrop
VIX 18.4 · elevated
Equity put/call 0.55
Technical
price trend
50 / 200-day cross
No cross
Price vs 50-day avg
−25%
below
RSI (14)
41
neutral
MACD trend
Positive
52-week position
12%
near low
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
Not enough data for a confident read.
Sentiment
smart money
Trend (MA cross)
No cross
50/200-day averages unavailable
Institutional flow
Flat
No 13F holder data
Insider flow
Accumulating
Net +$200.0K over 90 days · 0% sells
Short interest
Rising
4.24% of float · ▲ +100.6% MoM · 2.1 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
No 13F holder history
Squeeze score
55
elevated · 0–100
Fundamentals
Not enough data for a confident read.
Quant / Vol
risk profile
Volatility
95%
annualized · 1-yr
Max drawdown
−49%
past year
ATR
11.6%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Sell
50 / 200-day cross
No cross
Neutral
Price vs 50-day avg
−25%
Bearish
RSI (14)
41
Neutral
MACD trend
Positive
Bullish
52-week position
12%
Bearish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Mixed
Trend (MA cross)
No cross
50/200-day averages unavailable
Institutional flow
Flat
No 13F holder data
Insider flow
Accumulating
Net +$200.0K over 90 days · 0% sells
Short interest
Rising
4.24% of float · ▲ +100.6% MoM · 2.1 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
No 13F holder history
Price context
position in its available closing range
Range low $17
Now $19 · 12%
Range high $33
vs 50-day avg -25%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Total other income | $137.8M | the three months ended June 30, 2026 filing | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
APMD
this stock
Apnimed, Inc.
|
$771.42M | — | — | — | 4.2% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$130.07B | +13.5% | +46.2% | 29.9 | 1.8% |
|
MRNA
Moderna, Inc.
|
$90.58B | +720.9% | +4.3% | — | 7.7% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$80.51B | +4.6% | +20.8% | 19.4 | 2.1% |
|
CSLLY
Csl Ltd
|
$64.50B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionShort & Settlement
Smart Money
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| APMD | +3.8% | -27.4% | — | -15.5% | — |
| SPY | -1.2% | -0.6% | +8.1% | +0.8% | +12.8% |
| vs SPY | +5.0% | -26.9% | — | -16.4% | — |